Recovery research fieldbook Evidence, not treatment advice
Recovery archive

Published recovery field note

TB-500 Fragment (17-23) Legal Status: FDA Regulations 2026

Understand the legal considerations for TB-500 Fragment (17-23), its FDA status, compounding regulations, and patient implications in 2026.

Context first

Study findings do not automatically establish clinical benefit, safety, dosing, or suitability for an individual.

Is TB-500 Fragment (17-23) Legal? FDA Status and Regulations Explained (2026)

PeptideClinicLocator Editorial Team

Related Tools

Find a Peptide Therapy Clinic Near You

Browse our directory of verified peptide therapy clinics across the United States. Compare providers, read reviews, and request a consultation.

MyPeptideMatch.com does not provide medical advice. Always consult a qualified healthcare provider before starting any peptide therapy. Regulatory status may change.

Continue Reading

Is Follistatin 315 Legal? FDA Status and Regulations Explained (2026)

Explore the legal status of Follistatin 315, its FDA classification, compounding legality, and implications for patients seeking peptide therapy.

Is GHK-Cu Legal? FDA Status and Regulations Explained (2026)

Explore the FDA status, compounding legality, and enforcement actions related to GHK-Cu peptide as of 2026. Understand what 'research use only' entails and practical implications for patients.

Is AICAR Legal? FDA Status and Regulations Explained (2026)

Explore the FDA status and legal regulations surrounding AICAR, a research compound with potential metabolic benefits. Understand its compounding legality and what patients need to know.

Connected topics

Follow this recovery question